Rallybio Corporation announced that results from the RLYB212 Phase 1b proof-of-concept study will be presented at the 31stCongress of the International Society on Thrombosis and Haemostasis (ISTH), which will take place in Montreal from June 24-28. RLYB212 is an anti-HPA-1a monoclonal antibody being developed for the prevention of fetal and neonatal alloimmune thrombocytopenia (FNAIT).